Furthermore, bevacizumab is the first therapy line against mCRC, demonstrating the fact that VEGF is a key mediator of tumor angiogenesis, and blocking angiogenesis is an important strategy to treat human cancer [167]. Here, VEGFA is linked to neoplasm.